


-138-

## CLAIMS

1. A compound of the Formula I



Formula I

wherein:

R1 is NHR10, (substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>alkyl)NHR10 or (unsubstituted or substituted C<sub>3</sub>-C<sub>8</sub> cycloalkyl)NHR10;

R10 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>alkyl(OH), C<sub>1</sub>-C<sub>6</sub>alkylidenyl(OH)R11, or an amino protecting group;

R11 is C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>1</sub>-C<sub>6</sub>alkyl(O)C<sub>1</sub>-C<sub>6</sub>alkyl, C(O)O-C<sub>1</sub>-C<sub>6</sub>alkyl, aryl, or C<sub>1</sub>-C<sub>6</sub>alkylaryl;

R2 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, aryl, or C<sub>1</sub>-C<sub>6</sub>alkylaryl;

R3 is unsubstituted or substituted aryl, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkylaryl, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkylaryl, unsubstituted or substituted C<sub>3</sub>-C<sub>8</sub> cycloalkyl, unsubstituted or substituted (C<sub>1</sub>-C<sub>6</sub> alkyl) C<sub>3</sub>-C<sub>8</sub> cycloalkyl, indoliny;

R4 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, aryl, C<sub>1</sub>-C<sub>6</sub>alkylaryl, or C<sub>2</sub>-C<sub>6</sub>alkenyl;

R5 is hydrogen, aryl, C<sub>1</sub>-C<sub>6</sub>alkylaryl, hydroxy, C<sub>1</sub>-C<sub>6</sub>alkoxy, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl;

R6 and R7 are independently hydrogen, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl, unsubstituted or substituted C<sub>2</sub>-C<sub>6</sub>alkenyl, or R6 and R7 together with the carbon atom to

-139-

which they are attached form a carbocyclic ring of up to 8 atoms which is optionally partly unsaturated or a substituted C<sub>3</sub>-C<sub>8</sub> cycloalkyl group which is optionally partly unsaturated;

5 R<sub>8</sub> is hydrogen, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl, unsubstituted or substituted aryl, unsubstituted or substituted (C<sub>1</sub>-C<sub>6</sub>alkyl)C<sub>3</sub>-C<sub>8</sub>cycloalkyl, or unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkylaryl;

10 R<sub>9</sub> is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>2</sub>-C<sub>6</sub>alkynyl, C<sub>3</sub>-C<sub>8</sub>cycloalkyl, C<sub>3</sub>-C<sub>8</sub>cycloalkenyl, cyano, unsubstituted or substituted aryl, unsubstituted or substituted -O-aryl, unsubstituted or substituted -N-aryl, unsubstituted or substituted -S-aryl, -aryl-aryl(K<sub>1</sub>)(K<sub>2</sub>), -O-aryl-aryl(K<sub>1</sub>)(K<sub>2</sub>), -N-aryl-aryl(K<sub>1</sub>)(K<sub>2</sub>), -S-aryl-aryl(K<sub>1</sub>)(K<sub>2</sub>), -O-  
15 C<sub>1</sub>-C<sub>6</sub>alkyl, or C<sub>1</sub>-C<sub>6</sub>alkylaryl, wherein K<sub>1</sub> is halo or -CF<sub>3</sub>, and K<sub>2</sub> is hydrogen, halo or -CF<sub>3</sub> or K<sub>1</sub> and K<sub>2</sub> together form a methylenedioxy group;

Q is -S(O)<sub>2</sub>- or -C(O)-; and

m is a number selected from 1 or 2;

20 provided that R<sub>1</sub> is (substituted C<sub>1</sub>-C<sub>6</sub>alkyl)NHR<sub>10</sub> or (unsubstituted or substituted C<sub>3</sub>-C<sub>8</sub> cycloalkyl)NHR<sub>10</sub>; or

R<sub>5</sub> is hydroxy, C<sub>1</sub>-C<sub>6</sub>alkoxy, or substituted C<sub>1</sub>-C<sub>6</sub>alkyl; or

R<sub>6</sub> and R<sub>7</sub> are independently unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl or unsubstituted or substituted C<sub>2</sub>-  
25 C<sub>6</sub>alkenyl with the proviso that at least one group is substituted; or


R<sub>6</sub> is hydrogen and R<sub>7</sub> is substituted C<sub>1</sub>-C<sub>6</sub>alkyl or substituted C<sub>2</sub>-C<sub>6</sub>alkenyl; or

30 R<sub>6</sub> and R<sub>7</sub> together with the carbon atom to which they are attached may form a substituted C<sub>3</sub>-C<sub>8</sub> cycloalkyl group which is optionally partly unsaturated; or

R<sub>8</sub> is substituted C<sub>1</sub>-C<sub>6</sub>alkyl, substituted aryl, unsubstituted or substituted (C<sub>1</sub>-C<sub>6</sub>alkyl)C<sub>3</sub>-C<sub>8</sub>cycloalkyl or substituted C<sub>1</sub>-C<sub>6</sub>alkylaryl;

or a pharmaceutically acceptable salt or solvate thereof.

- 5           2. A compound according to claim 1 having Formula I



Formula I

wherein:

- 10           R1 is NHR10 or C<sub>1</sub>-C<sub>6</sub>alkylNHR10;  
             R10 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>alkyl(OH), C<sub>1</sub>-C<sub>6</sub>alkylidenyl(OH)R11, or an amino protecting group;  
             R11 is C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>1</sub>-C<sub>6</sub>alkyl(O)C<sub>1</sub>-C<sub>6</sub>alkyl, C(O)O-C<sub>1</sub>-C<sub>6</sub>alkyl, aryl, or C<sub>1</sub>-C<sub>6</sub>alkylaryl;  
 15           R2 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, aryl, or C<sub>1</sub>-C<sub>6</sub>alkylaryl;  
             R3 is unsubstituted or substituted aryl, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkylaryl, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkylaryl, unsubstituted or substituted C<sub>3</sub>-C<sub>8</sub> cycloalkyl, unsubstituted or substituted (C<sub>1</sub>-C<sub>6</sub> alkyl)  
 20           C<sub>3</sub>-C<sub>8</sub> cycloalkyl, indolinyl;  
             R4 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, aryl, C<sub>1</sub>-C<sub>6</sub>alkylaryl, or C<sub>2</sub>-C<sub>6</sub>alkenyl;  
             R5 is hydroxy, C<sub>1</sub>-C<sub>6</sub>alkoxy, or substituted C<sub>1</sub>-C<sub>6</sub>alkyl;  
             R6 and R7 are independently hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, or R6 and R7 together with the carbon atom to  
 25           which they are attached form a carbocyclic ring of up to 8 atoms which is optionally partly unsaturated;

-141-

R8 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, aryl, or C<sub>1</sub>-C<sub>6</sub>alkylaryl;


R9 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>2</sub>-C<sub>6</sub>alkynyl, C<sub>3</sub>-C<sub>8</sub>cycloalkyl, C<sub>3</sub>-C<sub>8</sub>cycloalkenyl, cyano, unsubstituted or substituted aryl, unsubstituted or substituted -O-aryl, unsubstituted or substituted -N-aryl, unsubstituted or substituted -S-aryl, -aryl-aryl(K1)(K2), -O-aryl-aryl(K1)(K2), -N-aryl-aryl(K1)(K2), -S-aryl-aryl(K1)(K2), -O-C<sub>1</sub>-C<sub>6</sub>alkyl, or C<sub>1</sub>-C<sub>6</sub>alkylaryl, wherein K1 is halo or -CF<sub>3</sub>, and K2 is hydrogen, halo or -CF<sub>3</sub> or K1 and K2 together form a methylenedioxy group;

Q is -S(O)<sub>2</sub>- or -C(O)-;

m is a number selected from 1 or 2;

or a pharmaceutically acceptable salt or solvate thereof.

3. A compound according to claim 1 having Formula I



Formula I

wherein:

R1 is NHR10 or C<sub>1</sub>-C<sub>6</sub>alkylNHR10;

R10 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>alkyl(OH), C<sub>1</sub>-C<sub>6</sub>alkylidenyl(OH)R11, or an amino protecting group;

R11 is C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>1</sub>-C<sub>6</sub>alkyl(O)C<sub>1</sub>-C<sub>6</sub>alkyl,

C(O)O-C<sub>1</sub>-C<sub>6</sub>alkyl, aryl, or C<sub>1</sub>-C<sub>6</sub>alkylaryl;

R2 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, aryl, or C<sub>1</sub>-C<sub>6</sub>alkylaryl;

R3 is unsubstituted or substituted aryl, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkylaryl, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkylaryl, unsubstituted or substituted C<sub>3</sub>-C<sub>8</sub> cycloalkyl, unsubstituted or substituted (C<sub>1</sub>-C<sub>6</sub> alkyl)

5 C<sub>3</sub>-C<sub>8</sub> cycloalkyl, indolinyll;

R4 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, aryl, C<sub>1</sub>-C<sub>6</sub>alkylaryl, or C<sub>2</sub>-C<sub>6</sub>alkenyl;

R5 is hydrogen, aryl, C<sub>1</sub>-C<sub>6</sub>alkylaryl, hydroxy, C<sub>1</sub>-C<sub>6</sub>alkoxy, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl;

10 R6 and R7 are independently hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, or R6 and R7 together with the carbon atom to which they are attached form a carbocyclic ring of up to 8 atoms which is optionally partly unsaturated;

R8 is substituted C<sub>1</sub>-C<sub>6</sub>alkyl, substituted aryl, unsubstituted or substituted (C<sub>1</sub>-C<sub>6</sub>alkyl)C<sub>3</sub>-C<sub>8</sub>cycloalkyl or substituted C<sub>1</sub>-C<sub>6</sub>alkylaryl;

R9 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>2</sub>-C<sub>6</sub>alkynyl, C<sub>3</sub>-C<sub>8</sub>cycloalkyl, C<sub>3</sub>-C<sub>8</sub>cycloalkenyl, cyano, unsubstituted or substituted aryl, unsubstituted or substituted -O-aryl, unsubstituted or substituted -N-aryl, unsubstituted or substituted -S-aryl, -aryl-aryl(K1)(K2), -O-aryl-aryl(K1)(K2), -N-aryl-aryl(K1)(K2), -S-aryl-aryl(K1)(K2), -O-C<sub>1</sub>-C<sub>6</sub>alkyl, or C<sub>1</sub>-C<sub>6</sub>alkylaryl, wherein K1 is halo or -CF<sub>3</sub>, and K2 is hydrogen, halo or -CF<sub>3</sub> or K1 and K2 together form  
25 a methylenedioxy group;

Q is -S(O)<sub>2</sub>- or -C(O)-;


m is a number selected from 1 or 2;

or a pharmaceutically acceptable salt or solvate thereof.

30

4. A compound according to claim 1 having Formula I

-143-



Formula I

wherein:

R1 is NHR10 or C<sub>1</sub>-C<sub>6</sub>alkylNHR10;

5 R10 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>alkyl(OH), C<sub>1</sub>-C<sub>6</sub>alkylidenyl(OH)R11, or an amino protecting group;

R11 is C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>1</sub>-C<sub>6</sub>alkyl(O)C<sub>1</sub>-C<sub>6</sub>alkyl, C(O)O-C<sub>1</sub>-C<sub>6</sub>alkyl, aryl, or C<sub>1</sub>-C<sub>6</sub>alkylaryl;

R2 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, aryl, or C<sub>1</sub>-C<sub>6</sub>alkylaryl;

10 R3 is unsubstituted or substituted aryl, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkylaryl, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkylaryl, unsubstituted or substituted C<sub>3</sub>-C<sub>8</sub> cycloalkyl, unsubstituted or substituted (C<sub>1</sub>-C<sub>6</sub> alkyl) C<sub>3</sub>-C<sub>8</sub> cycloalkyl, indoliny;

15 R4 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, aryl, C<sub>1</sub>-C<sub>6</sub>alkylaryl, or C<sub>2</sub>-C<sub>6</sub>alkenyl;

R5 is hydrogen, aryl, C<sub>1</sub>-C<sub>6</sub>alkylaryl, hydroxy, C<sub>1</sub>-C<sub>6</sub>alkoxy, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl;

20 R6 and R7 are independently unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl or unsubstituted or substituted C<sub>2</sub>-C<sub>6</sub>alkenyl with the proviso that at least one group is substituted; or

R6 is hydrogen and R7 is substituted C<sub>1</sub>-C<sub>6</sub>alkyl or substituted C<sub>2</sub>-C<sub>6</sub>alkenyl; or

25 or R6 and R7 together with the carbon atom to which they are attached may form a substituted C<sub>3</sub>-C<sub>8</sub> cycloalkyl group which is optionally partly unsaturated;

-144-

R8 is hydrogen, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl, unsubstituted or substituted aryl, unsubstituted or substituted (C<sub>1</sub>-C<sub>6</sub>alkyl)C<sub>3</sub>-C<sub>8</sub>cycloalkyl or unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkylaryl;

5 R9 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>2</sub>-C<sub>6</sub>alkynyl, C<sub>3</sub>-C<sub>8</sub>cycloalkyl, C<sub>3</sub>-C<sub>8</sub>cycloalkenyl, cyano, unsubstituted or substituted aryl, unsubstituted or substituted -O-aryl, unsubstituted or substituted -N-aryl, unsubstituted or substituted -S-aryl, -aryl-aryl(K1)(K2), -O-aryl-aryl(K1)(K2), -N-aryl-aryl(K1)(K2), -S-aryl-aryl(K1)(K2), -O-C<sub>1</sub>-C<sub>6</sub>alkyl, or C<sub>1</sub>-C<sub>6</sub>alkylaryl, wherein K1 is halo or -CF<sub>3</sub>, and K2 is hydrogen, halo or -CF<sub>3</sub> or K1 and K2 together form a methylenedioxy group;


Q is -S(O)<sub>2</sub>- or -C(O)-;

15 m is a number selected from 1 or 2;

or a pharmaceutically acceptable salt or solvate thereof.

5. A compound according to claim 1 having Formula I

20



Formula I

wherein:

25 R1 is (substituted C<sub>1</sub>-C<sub>6</sub>alkyl)NHR10 or (unsubstituted or substituted C<sub>3</sub>-C<sub>8</sub> cycloalkyl)NHR10;

R10 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>alkyl(OH), C<sub>1</sub>-C<sub>6</sub>alkylidenyl(OH)R11, or an amino protecting group;

-145-

R11 is C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>1</sub>-C<sub>6</sub>alkyl(O)C<sub>1</sub>-C<sub>6</sub>alkyl, C(O)O-C<sub>1</sub>-C<sub>6</sub>alkyl, aryl, or C<sub>1</sub>-C<sub>6</sub>alkylaryl;

R2 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, aryl, or C<sub>1</sub>-C<sub>6</sub>alkylaryl;

5 R3 is unsubstituted or substituted aryl, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkylaryl, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkylaryl, unsubstituted or substituted C<sub>3</sub>-C<sub>8</sub> cycloalkyl, unsubstituted or substituted (C<sub>1</sub>-C<sub>6</sub> alkyl) C<sub>3</sub>-C<sub>8</sub> cycloalkyl, indoliny;

10 R4 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, aryl, C<sub>1</sub>-C<sub>6</sub>alkylaryl, or C<sub>2</sub>-C<sub>6</sub>alkenyl;

R5 is hydrogen, aryl, C<sub>1</sub>-C<sub>6</sub>alkylaryl, hydroxy, C<sub>1</sub>-C<sub>6</sub>alkoxy, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl;

15 R6 and R7 are independently hydrogen, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl, unsubstituted or substituted C<sub>2</sub>-C<sub>6</sub>alkenyl, or R6 and R7 together with the carbon atom to which they are attached form a carbocyclic ring of up to 8 atoms which is optionally partly unsaturated or a substituted C<sub>3</sub>-C<sub>8</sub> cycloalkyl group which is optionally partly unsaturated;

20 R8 is hydrogen, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl, unsubstituted or substituted aryl, unsubstituted or substituted (C<sub>1</sub>-C<sub>6</sub>alkyl)C<sub>3</sub>-C<sub>8</sub>cycloalkyl or unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkylaryl;

25 R9 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>2</sub>-C<sub>6</sub>alkynyl, C<sub>3</sub>-C<sub>8</sub>cycloalkyl, C<sub>3</sub>-C<sub>8</sub>cycloalkenyl, cyano, unsubstituted or substituted aryl, unsubstituted or substituted -O-aryl, unsubstituted or substituted -N-aryl, unsubstituted or substituted -S-aryl, -aryl-aryl(K1)(K2), -O-aryl-aryl(K1)(K2), -N-aryl-aryl(K1)(K2), -S-aryl-aryl(K1)(K2), -O-C<sub>1</sub>-C<sub>6</sub>alkyl, or C<sub>1</sub>-C<sub>6</sub>alkylaryl, wherein K1 is halo or -CF<sub>3</sub>,  
30 and K2 is hydrogen, halo or -CF<sub>3</sub> or K1 and K2 together form a methylenedioxy group;

Q is -S(O)<sub>2</sub>- or -C(O)-;

m is a number selected from 1 or 2;




-146-

or a pharmaceutically acceptable salt or solvate thereof.

6. A compound according to claim 2 wherein R1 is

5



or a pharmaceutically acceptable salt or solvate thereof.


10 7. A compound according to claim 2 or 6 wherein R6 and R7 are each C<sub>1</sub>-C<sub>3</sub> alkyl or form a five or six membered carbocyclic ring; or a pharmaceutically acceptable salt or solvate thereof.

15 8. A compound according to any one of claims 2, 6 or 7 wherein R5 is hydroxy, C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>1</sub>-C<sub>6</sub>alkyl which is substituted by hydroxy or C<sub>1</sub>-C<sub>6</sub>alkyl which is substituted by one, two, or three halo atoms, or a pharmaceutically acceptable salt or solvate thereof.

20

9. A compound according to any one of claims 2 or 6 to 8 wherein R8 is hydrogen, methyl, ethyl or benzyl, or a pharmaceutically acceptable salt or solvate thereof.

25 10. A compound according to claim 3 wherein R1 is



or a pharmaceutically acceptable salt or solvate thereof.

-147-


11. A compound according to claim 3 or 10 wherein R6 and R7 are each C<sub>1</sub>-C<sub>3</sub> alkyl or form a five or six membered carbocyclic ring, or a pharmaceutically acceptable salt or solvate thereof.

5

12. A compound according to any one of claims 3, 10 or 11 wherein R5 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>1</sub>-C<sub>6</sub>alkyl which is substituted by hydroxy or C<sub>1</sub>-C<sub>6</sub>alkyl which is substituted by one, two, or three halo atoms, or a  
10 pharmaceutically acceptable salt or solvate thereof.

13. A compound according to any one of claims 3 or 10 to 12 wherein R8 is C<sub>1</sub>-C<sub>6</sub>alkyl which is substituted by hydroxy or C<sub>1</sub>-C<sub>6</sub>alkyl which is substituted by one, two, or  
15 three halo atoms, phenyl substituted by one, two, or three halo atoms or benzyl substituted by one, two, or three halo atoms, or a pharmaceutically acceptable salt or solvate thereof.

20 14. A compound according to claim 4 wherein R1 is



or a pharmaceutically acceptable salt or solvate thereof.

25 15. A compound according to claim 4 or 14 wherein R6 and R7 are independently C<sub>1</sub>-C<sub>6</sub>alkyl or C<sub>2</sub>-C<sub>6</sub>alkenyl, in which one or both groups are substituted by one, two, or three halo atoms; or R6 is hydrogen and R7 is C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl which is substituted by one, two, or three halo  
30 atoms; or R6 and R7 together with the carbon atom to which they are attached may form a C3-C8cycloalkyl group which is

-148-




optionally partly unsaturated and which is substituted by one, two, or three halo atoms, or a pharmaceutically acceptable salt or solvate thereof.

5        16. A compound according to any one of claims 4, 14 or 15 wherein R5 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>1</sub>-C<sub>6</sub>alkyl which is substituted by hydroxy or C<sub>1</sub>-C<sub>6</sub>alkyl which is substituted by one, two, or three halo atoms, or a pharmaceutically acceptable salt or solvate thereof.

10

17. A compound according to any one of claims 4 or 14-16 wherein R8 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, (C<sub>1</sub>-C<sub>6</sub>alkyl)<sub>3</sub>-C<sub>8</sub>cycloalkyl, benzyl, 1-phenylethyl, C<sub>1</sub>-C<sub>6</sub>alkyl which is substituted by hydroxy, methoxy, CONH<sub>2</sub>, or CON(CH<sub>3</sub>)<sub>2</sub>, or C<sub>1</sub>-15 C<sub>6</sub>alkyl which is substituted by one, two, or three halo atoms, phenyl substituted by one, two, or three halo atoms or benzyl substituted by one, two, or three halo atoms, or a pharmaceutically acceptable salt or solvate thereof.

20        18. A compound according to claim 5 wherein R1 is selected from -C(CH<sub>3</sub>)(CH<sub>2</sub>OH)NH<sub>2</sub>, -C(CH<sub>2</sub>F)<sub>2</sub>NH<sub>2</sub>, -C(CH<sub>2</sub>F)(CH<sub>2</sub>CH<sub>2</sub>F)NH<sub>2</sub>, -C(CF<sub>3</sub>)(CH<sub>3</sub>)NH<sub>2</sub>, -C(CH<sub>2</sub>CH<sub>2</sub>F)<sub>2</sub>NH<sub>2</sub>,



-C(CH<sub>2</sub>CH<sub>3</sub>)(CH<sub>2</sub>CF<sub>3</sub>)NH<sub>2</sub>,

or a pharmaceutically acceptable salt or solvate thereof.

25

19. A compound according to claim 5 or 18 wherein R6 and R7 are each C<sub>1</sub>-C<sub>3</sub> alkyl or form a five or six membered carbocyclic ring; or R6 and R7 are independently C<sub>1</sub>-C<sub>6</sub>alkyl or C<sub>2</sub>-C<sub>6</sub>alkenyl, in which one or both groups are substituted 30 by one, two, or three halo atoms; or R6 is hydrogen and R7 is C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl which is substituted by one, two, or three halo atoms; or R6 and R7 together with the carbon

-149-


atom to which they are attached may form a C3-C8cycloalkyl group which is optionally partly unsaturated and which is substituted by one, two, or three halo atoms; or a pharmaceutically acceptable salt or solvate thereof.

5

20. A compound according to any one of claims 5, 18 or 19 wherein R5 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>1</sub>-C<sub>6</sub>alkyl which is substituted by hydroxy or C<sub>1</sub>-C<sub>6</sub>alkyl which is substituted by one, two, or three halo atoms, or a  
10 pharmaceutically acceptable salt or solvate thereof.

21. A compound according to any one of claims 5 or 18 to 20 wherein R8 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, benzyl, C<sub>1</sub>-C<sub>6</sub>alkyl which is substituted by hydroxy, C<sub>1</sub>-C<sub>6</sub>alkyl which is  
15 substituted by one, two, or three halo atoms, phenyl substituted by one, two, or three halo atoms or benzyl substituted by one, two, or three halo atoms, or a pharmaceutically acceptable salt or solvate thereof.

20 22. A compound according to any one of claims 1 to 21 having Formula II



Formula II

25 wherein

R1, R2, R3, R5, R6, R7, R8, R9 and Q are as defined in any one of claims 1 to 21 or a pharmaceutically acceptable salt or solvate thereof.

5           23. A compound according to any one of claims 1 to 22 wherein R3 is selected from unsubstituted or substituted aryl, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkylaryl, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkylaryl, unsubstituted or substituted (C<sub>1</sub>-C<sub>6</sub> alkyl) C<sub>3</sub>-C<sub>8</sub> cycloalkyl;  
10 or a pharmaceutically acceptable salt or solvate thereof.

          24. A compound according to claim 23 wherein the unsubstituted or substituted aryl group, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkylaryl or unsubstituted or substituted  
15 C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkylaryl group contains an aryl moiety selected from phenyl, thiazolyl, pyridyl, naphthyl, thienyl, oxazolyl, isoxazolyl and indolyl optionally substituted by from one to three groups independently selected from C<sub>1</sub>-C<sub>6</sub> alkyl, -OC<sub>1</sub>-C<sub>6</sub> alkyl, -OCF<sub>3</sub>, amide, aryl, aryloxy, SO<sub>2</sub>(C<sub>1</sub>-  
20 alkyl), SO<sub>2</sub>CF<sub>3</sub>, NHamide, carboxamide, sulfonamide, NHsulfonamide, imide, hydroxy, carboxy, nitro, halo, tri(chloro or fluoro)methyl, and cyano; or a pharmaceutically acceptable salt or solvate thereof.

25           25. A compound according to any one of claims 1 to 24 wherein R3 is an unsubstituted or substituted aryl group, an unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub> alkylaryl group or an unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)- C<sub>1</sub>-C<sub>6</sub>alkyl aryl group wherein:

30           the C<sub>1</sub>-C<sub>6</sub>alkyl moiety within the unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub> alkylaryl group is methyl, ethyl or propyl;

the C<sub>1</sub>-C<sub>6</sub>alkyl(O) - C<sub>1</sub>-C<sub>6</sub>alkyl moiety within the unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O) - C<sub>1</sub>-C<sub>6</sub>alkyl aryl group is a moiety of formula -CH<sub>2</sub>OCH<sub>2</sub>-;

the unsubstituted or substituted aryl moiety is phenyl,  
5 thiazolyl, pyridyl, naphthyl, thienyl, oxazolyl, isoxazolyl and indolyl which is unsubstituted or substituted by from one to three groups independently selected from halo (preferably chloro or fluoro), methyl, methoxy, cyano, SO<sub>2</sub>Me, trifluoromethyl, and trifluoromethoxy. Most  
10 preferably the unsubstituted aryl moiety is phenyl, naphthyl, thiazolyl or indolyl and the substituted aryl moiety in said groups is 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,3-difluorophenyl, 2,4-difluorophenyl, 2,5-difluorophenyl, 2,6-difluorophenyl, 3,4-difluorophenyl, 3,5-  
15 difluorophenyl, 2,4,6-trifluorophenyl, 2,3,4-trifluorophenyl, 2,4,5-trifluorophenyl, 2,3,6-trifluorophenyl, 2,3,5-trifluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,6-dichlorophenyl, 2,3-dichlorophenyl, 2,4-dichlorophenyl, 2,5-dichlorophenyl, 2-  
20 chloro-4-fluorophenyl, 2-methylphenyl, 2,6-difluoro-3-methylphenyl, 3,6-difluoro-2-chlorophenyl, 2-fluoro-6-chlorophenyl, 2-fluoro-3-chlorophenyl, 2-fluoro-4-chlorophenyl, 2,6-difluoro-3-chlorophenyl, 4-trifluoromethylphenyl, 3-trifluoromethylphenyl, 2-  
25 trifluoromethylphenyl, 2-fluoro-5-trifluoromethylphenyl, 2-fluoro-3-trifluoromethylphenyl, 2-fluoro-6-trifluoromethylphenyl, 2-chloro-3-trifluoromethylphenyl, 4-trifluoromethoxyphenyl, 3-trifluoromethoxyphenyl, 2-trifluoromethoxyphenyl, 2-cyanophenyl, 3-cyanophenyl, 4-  
30 cyanophenyl, 4-methanesulphonylphenyl, and 2-methylthiazolyl.;

or a pharmaceutically acceptable salt or solvate thereof.

26. A compound according to any one of claims 1 to 25 wherein R3 is selected from the group consisting of unsubstituted or substituted aryl, C<sub>1</sub>-C<sub>6</sub>alkylaryl, C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkylaryl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, (C<sub>1</sub>-C<sub>6</sub> alkyl) C<sub>3</sub>-C<sub>8</sub> cycloalkyl, indolyl, indoliny, (C<sub>1</sub>-C<sub>6</sub> alkyl) indolyl.

27. A compound according to any one of claims 1 to 26 wherein R4 is hydrogen or methyl, or a pharmaceutically acceptable salt or solvate thereof.

10

28. A compound according to any one of claims 1 to 27 wherein R9 is selected from the group consisting of unsubstituted or substituted thienyl, unsubstituted or substituted naphthyl, unsubstituted or substituted phenoxy and unsubstituted or substituted phenyl; wherein the substituents when present are each independently selected from the group consisting of halo, methyl, ethyl, propyl, t-butyl, trifluoromethyl, trifluoromethoxy, methoxy, ethoxy, cyano, methylsulphonyl, phenyl, phenoxy, thienyl, pyridyl, thiazolyl, oxazolyl, nitro, CONH<sub>2</sub>, furanyl, benzothiophenyl and benzofuranyl; or a pharmaceutically acceptable salt or solvate thereof.

29. A compound of according to claim 28 wherein R9 is selected from phenyl, 4-methylsulphonylphenyl, 3-methylsulphonylphenyl, 4-fluorophenyl, 2-fluorophenyl, 3-fluorophenyl, 3-chlorophenyl, 2-chlorophenyl, 4-chlorophenyl, 4-t-butylphenyl, 4-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-nitrophenyl, 3-nitrophenyl, 4-bromophenyl, 3-bromophenyl, 2-bromophenyl, 4-methylphenyl, 3-methylphenyl, 4-phenylphenyl, 3-phenylphenyl, 4-phenoxyphenyl, 3-phenoxyphenyl, 4-cyanophenyl, 3-cyanophenyl, 4-carbamoylphenyl, 4-methoxyphenyl, 3-methoxyphenyl, thienyl, thiazolyl, pyridyl, phenoxy, 4-


-153-

chlorophenoxy, 2,3-dichlorophenyl, 3,4-dichlorophenyl,  
 naphthyl, oxazolyl, 2,4-difluorophenyl, 3,4-difluorophenyl,  
 3,5-difluorophenyl, 2,3-difluorophenyl, 2,6-difluorophenyl,  
 2,5-difluorophenyl, 2-fluoro-3-chlorophenyl, 4-ethylphenyl,  
 5 4-ethoxyphenyl 3,4,5-trifluorophenyl, 3-fluoro-4-  
 chlorophenyl and 4-carbamoylphenyl;  
 or a pharmaceutically acceptable salt or solvate thereof.

30. A pharmaceutical formulation comprising one or  
 10 more compounds according to any one of claims 1 to 29 or a  
 pharmaceutically acceptable salt or solvate thereof,  
 and one or more pharmaceutically acceptable diluents or  
 carriers therefor.

15 31. A pharmaceutical formulation according to claim 30  
 wherein the formulation further comprises one or more growth  
 hormone secretagogue compounds and/or a bone-antiresorptive  
 agent.

20 32. A process for producing a compound of Formula I as  
 defined in any one of claims 1 to 29 comprising coupling a  
 compound of Formula XI or XIb




25

with a compound of formula XIII



-154-




XIII

wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and Q are as defined in any one of claims 1 to 29.

5

33. A process for producing a compound of Formula I as defined in any one of claims 1 to 29 comprising deprotecting a compound of Formula




10

wherein R2, R3, R4, R5, R6, R7, R8, R9, m and Q are as defined in any one of claims 1 to 29, and PG is an amino protecting group.

15

34. A process for producing a compound of Formula I as defined in any one of claims 1 to 29 comprising coupling a compound of Formula

-155-



with a compound of formula XIV

HOOC-R1

XIV

wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and Q are as defined in any one of claims 1 to 29.

35. A compound according to any one of claims 1 to 29 for the treatment of the human or animal body by therapy.

36. Use of a compound according to any one of claims 1 to 29 or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for the treatment of a physiological condition which may be modulated or ameliorated by an increase in endogenous growth hormone.

37. A method of using a compound of any one of claims 1 to 5 or a pharmaceutically acceptable salt or solvate thereof for the treatment of a physiological condition which may be modulated or ameliorated by an increase in endogenous growth hormone, which method comprises administering to an animal in need of said treatment an effective amount of a compound of formula I.